These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31107640)

  • 1. Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Hum Vaccin Immunother; 2019; 15(7-8):1942-1948. PubMed ID: 31107640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The healthcare costs of treating human papillomavirus-related cancers in Norway.
    Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
    BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
    Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
    Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
    Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
    Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.
    Kim JJ; Simms KT; Killen J; Smith MA; Burger EA; Sy S; Regan C; Canfell K
    PLoS Med; 2021 Mar; 18(3):e1003534. PubMed ID: 33705382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
    Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Vaccine; 2018 Jul; 36(29):4362-4368. PubMed ID: 29887325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.